drugset / Trial / NCT00002372

A Study of 141W94 in Combination With Other Anti-HIV Drugs

NCT00002372

Phase 1 Completed 48 enrolled Glaxo Wellcome
Open-labelTreatment

Summary

To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing. To determine the steady-state pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after multiple oral dosing. To assess the safety and tolerability of multiple doses of 141W94 when combined with saquinavir, indinavir and nelfinavir.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amprenavir Other / unclassified Oral
Subject Amprenavir Other / unclassified
Subject INDINAVIR ANHYDROUS Other / unclassified Oral
Subject Nelfinavir Other / unclassified Oral
Subject Saquinavir Small molecule Oral